LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eli Lilly (LLY) is a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong growth potential driven by its GLP-1 franchise, positive analyst ratings, and recent congressional interest. Despite minor technical weaknesses, the overall outlook is favorable for long-term gains.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.364, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is near its support level of 1098.458, with resistance at 1134.395. Overall, technical indicators show mixed signals but lean slightly bearish in the short term.
Analysts have consistently raised price targets, with the highest at $1,400, citing strong GLP-1 momentum and obesity market growth.
Cathie Wood's recent purchase of LLY indicates confidence in the stock.
The stock has risen 40% over the past year, briefly surpassing a $1 trillion market cap.
Congress trading data shows balanced activity, with notable purchase transactions.
The MACD and RSI suggest short-term bearish momentum.
Concerns over a single hepatic failure case for Foundayo, although analysts and the company have downplayed its significance.
Financial data for the latest quarter is unavailable. However, analysts have highlighted strong Q1 results, upgraded guidance, and robust demand for key products like Mounjaro and Foundayo.
Analysts are overwhelmingly positive on LLY, with multiple firms raising price targets recently. The consensus is that the company's GLP-1 franchise and obesity market growth will drive long-term revenue and profit increases.
